Astrazeneca PLC 6-K, filed Dec 21, 2021
Astrazeneca PLC (AZN)
6-K
2021-12-21
For: 2021-12-21
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on December 21, 2021.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of December 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Ultomiris
accepted for FDA Priority Review for gMG
21 December 2021 07:00 GMT
Ultomiris regulatory submission accepted under FDA
Priority Review in the US for adults with generalised
myasthenia gravis
Submission based on positive Phase III trial in
which Ultomiris significantly
improved functional activities as measured by Myasthenia
Gravis-Activities of Daily Living Profile
The supplemental Biologics License Application (sBLA)
for Ultomiris (ravulizumab-cwvz) in adults
with generalised myasthenia gravis (gMG) has been
accepted for Priority Review by the US Food and Drug Administration
(FDA).
The FDA set a Prescription Drug User Fee Act date during the second
quarter of 2022, following use of a rare disease priority review
voucher by Alexion, AstraZeneca's Rare Disease group.
gMG is a rare, debilitating, chronic, autoimmune neuromuscular
disease that leads to a loss of muscle function and severe
weakness.1 The
diagnosed prevalence of gMG in the US is estimated at
64,000.2-10
Marc Dunoyer, Chief Executive Officer, Alexion, said:
"Soliris was the first new treatment approved for
this devastating disease in approximately 60 years, and this filing
for Ultomiris demonstrates Alexion's continued commitment
to improve outcomes for patients living with gMG. The Phase III
trial shows that Ultomiris may help a broader range of patients
including those with milder symptoms or who are earlier in their
treatment journey."
The sBLA submission in the US is based on results from the Phase
III trial of Ultomiris in gMG, which were announced by
Alexion in July 2021, and showed efficacy as early as Week 1 and
sustained for 52 weeks (26 weeks randomised controlled period + 26
weeks of open-label extension). In the trial, the
safety profile of Ultomiris was
consistent with that observed in Phase III trials
of Ultomiris in
paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic
uraemic syndrome (aHUS).
Regulatory submissions for Ultomiris for the treatment of gMG are also currently
under review with health authorities in the European Union (EU) and
Japan.
Notes
gMG
gMG is a rare autoimmune disorder characterised by severe
muscle weakness. In gMG, inflammation causes damage at the
connection point between nerve cells and the muscles they control
(known as the neuromuscular junction or NMJ). This damage leads to
a breakdown of communication between the brain and muscles, causing
loss of muscle function and severe weakness.1
About 85% of people with gMG produce specific antibodies that bind
to the surface of the cells at the NMJ.1 This
binding activates the complement cascade and causes the immune
system to attack the NMJ. People with gMG can suffer from initial
symptoms, such as slurred speech, droopy eyelids, double vision,
and lack of balance, which can often lead to more severe symptoms
like choking, impaired swallowing, extreme fatigue and even
episodes of respiratory failure.11,12
gMG can occur at any age, but it most commonly begins for women
before the age of 40 and for men after the age of
60.13-15
Clinical trial
The global Phase III randomised, double-blind, placebo-controlled,
multicentre 26-week trial evaluated the safety and efficacy
of Ultomiris in adults with gMG who were not previously
treated with a complement inhibitor medicine. The trial
enrolled 175 patients across North America, Europe, Asia-Pacific
and Japan. Participants were required to have a confirmed
myasthenia gravis diagnosis at least six months prior to the
screening visit with a positive serologic test for anti-AChR
antibodies, Myasthenia Gravis-Activities of Daily Living
Profile (MG-ADL) total score of at least 6 at trial entry and
Myasthenia Gravis Foundation of America Clinical Classification
Class II to IV at screening. There was no requirement for prior
treatment failure, and patients could stay on stable standard of
care medicines, with a few exceptions, for the duration of the
trial.16
Patients were randomised 1:1 to receive Ultomiris or placebo for a total of 26 weeks. Patients
received a single weight-based loading dose on Day 1, followed by
regular weight-based maintenance dosing beginning on Day 15, every
eight weeks. The primary endpoint of change from baseline in the
MG-ADL total score at Week 26 was assessed along with multiple
secondary endpoints evaluating improvement in disease-related and
quality-of-life measures.
Patients who completed the randomised controlled period were
eligible to continue into an open-label extension period evaluating
the safety and efficacy of Ultomiris for up to two years, which is ongoing. At
the time of the preliminary analysis of the open-label extension
period, 75 patients had completed 26 weeks of treatment, for a
total of 52 weeks of treatment.
Ultomiris
Ultomiris (ravulizumab),
the first and only long-acting C5 complement inhibitor, offers
immediate, complete, and sustained complement inhibition. The
medication works by inhibiting the C5 protein in the terminal
complement cascade, a part of the body's immune system. When
activated in an uncontrolled manner, the complement cascade
over-responds, leading the body to attack its own healthy
cells. Ultomiris is
administered intravenously every eight weeks or, for paediatric
patients less than 20kg, every four weeks, following a loading
dose. Ultomiris is
approved in the US for the treatment of adults and children (one
month of age and older) with PNH; in the EU for adults, as well as
for children (with a body weight of 10kg or above) and adolescents
with PNH who experience haemolysis with clinical symptom(s)
indicative of high disease activity, as well as for individuals who
are clinically stable after having been treated
with Soliris for at least the past six months; and in
Japan as a treatment for adults with PNH. It is also approved in
the US for aHUS to inhibit complement-mediated thrombotic
microangiopathy in adult and paediatric (one month of age and
older) patients, in the EU for the treatment of adults and children
with a body weight of at least 10kg with aHUS, as well as in Japan
for adults and children with aHUS.
Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca
focused on rare diseases, created following the 2021 acquisition of
Alexion Pharmaceuticals, Inc. As a leader in rare diseases for
nearly 30 years, Alexion is focused on serving patients and
families affected by rare diseases and devastating conditions
through the discovery, development and commercialisation of
life-changing medicines. Alexion focuses its research efforts on
novel molecules and targets in the complement cascade and its
development efforts on haematology, nephrology, neurology,
metabolic disorders, cardiology and ophthalmology. Headquartered in
Boston, Massachusetts, Alexion has offices around the globe and
serves patients in more than 50 countries.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1.
Howard, J. F., (2017). Myasthenia gravis: the role of complement at
the neuromuscular junction. Annals of The New York Academy of
Sciences, 1412(1), 113-128.
2.
Fang, F., Sveinsson, O., Thormar, G., Granqvist, M., Askling, J.,
Lundberg, I. E., . . . Piehl, F. (2015). The autoimmune spectrum of
myasthenia gravis: a Swedish population-based study. J Intern Med,
277(5), 594-604. doi:10.1111/joim.12310
3. Grob,
D., Brunner, N., Namba, T., and Pagala, M. (2008). Lifetime course
of myasthenia gravis. Muscle Nerve 37: 141-149.
4.
Suh, J., Goldstein, J. M., & Nowak, R. J. (2013). Clinical
Characteristics of Refractory Myasthenia Gravis Patients. The Yale
Journal of Biology and Medicine, 86(2), 255-260.
5.
Joensen P. (2014). Myasthenia gravis incidence in a general North
Atlantic isolated population. Acta Neurol Scand 130:
222-228.
6. Lefter,
S., Hardiman, O., and Ryan, AM. (2016). A population-based
epidemiologic study of adult neuromuscular disease in the Republic
of Ireland. Neurology 88:304-313.
7.
Pallaver, F., Riviera, A. P., Piffer, S., Ricciardi, R., Roni, R.,
Orrico, D., & Bonifati, D. M. (2011). Change in myasthenia
gravis epidemiology in Trento, Italy, after twenty years.
Neuroepidemiology, 36(4), 282-287.
doi:10.1159/000328863
8.
Santos, E., Coutinho, E., Moreira, I., Silva, A. M., Lopes, D.,
Costa, H., . . . Goncalves, G. (2016). Epidemiology of myasthenia
gravis in Northern Portugal: Frequency estimates and clinical
epidemiological distribution of cases. Muscle Nerve, 54(3),
413-421. doi:10.1002/mus.25068
9.
Robertson, NP., Deans, J., and Compston DAS. (1998). Myasthenia
gravis: a population based epidemiological study in Cambridgeshire,
England. J Neurol Neurosurg Psychiatry, 65:492-496.
10.
Zieda, A., Ravina, K., Glazere, I., Pelcere, L., Naudina, M. S.,
Liepina, L., . . . Kenina, V. (2018). A nationwide epidemiological
study of myasthenia gravis in Latvia. Eur J Neurol, 25(3), 519-526.
doi:10.1111/ene.13535
11. Myasthenia Gravis Fact
Sheet. (2020, April 27). National Institutes of Neurological
Disorders and Stroke. Available here.
Accessed October 2021.
12.
Ding J., Zhao, S., Ren, K., Dang, D., Li, H., Wu, F., Zhang, M.,
Li, Z., & Guo, J. (2020). Prediction of generalization of
ocular myasthenia gravis under immunosuppressive therapy in
Northwest China. BMC Neurology, 20(238).
13. Myasthenia Gravis.
National Organization for Rare Disorders (NORD).
Available here.
Accessed October 2021.
14. Howard, J. F. (2015).
Clinical Overview of MG. Available here.
Accessed October 2021.
15.
Sanders, D. B., Raja, S. M., Guptill J. T., Hobson-Webb, L. D.,
Juel, V. C., & Massey, J. M. (2020). The Duke myasthenia gravis
clinic registry: I. Description and demographics. Muscle &
Nerve, 63(2), 209-216.
16. ClinicalTrials.gov. Safety
and Efficacy Study of Ravulizumab in Adults With Generalized
Myasthenia Gravis. NCT Identifier: NCT03920293. Available
online. Accessed November 2021
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
21 December 2021
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|